Loading
A phase 1/2 trial of ACP-196 in glioma & glioblastoma, run by Acerta Pharma BV, active and no longer recruiting.
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) is a phase 1/2 interventional study registered as NCT02586857 by Acerta Pharma BV, with 24 participants enrolled, started 2016-01-25 and due to reach its primary completion in 2020-06-26. Interventions recorded: ACP-196. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
24 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2020-07-29), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.primary | Cohort 1 | 15 | 1 participants | - | - | link |
| Cohort 2 | 9 | 1 participants |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares AstraZeneca, Glioma & glioblastoma and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/